Editorial
Targeted therapy in small cell lung cancer: can DLL3 notch up a victory?
Translational Cancer Research
2017;
6
(Suppl 3)
:S453-S456
.
(26 May 2017)
Concomitant ALK/KRAS and ALK/EGFR mutations in non small cell lung cancer: different profile of response to target therapies
Translational Cancer Research
2017;
6
(Suppl 3)
:S457-S460
.
(26 May 2017)
Cognitive complaints in breast cancer patients treated with chemotherapy: a reality?
Translational Cancer Research
2017;
6
(Suppl 3)
:S461-S463
.
(26 May 2017)
RIPK1-TRAF2 interplay on the TNF/NF-κB signaling, cell death, and cancer development in the liver
Translational Cancer Research
2017;
6
(Suppl 3)
:S464-S468
.
(26 May 2017)
New players in the Bruton’s tyrosine kinase vs. ibrutinib match
Translational Cancer Research
2017;
6
(Suppl 3)
:S469-S471
.
(26 May 2017)
Increased lipid desaturation and ovarian cancer stem cells
Translational Cancer Research
2017;
6
(Suppl 3)
:S472-S475
.
(26 May 2017)
Long-term impact of staging breast magnetic resonance imaging—a risk for overtreatment?
Translational Cancer Research
2017;
6
(Suppl 3)
:S476-S478
.
(26 May 2017)
Portal vein tumor thrombus should not be considered as a contraindication for liver resection
Translational Cancer Research
2017;
6
(Suppl 3)
:S479-S480
.
(26 May 2017)
Eastern experience: surgical resection may be the first choice of treatment for selected hepatocellular carcinoma patients with portal vein tumor thrombus
Translational Cancer Research
2017;
6
(Suppl 3)
:S481-S485
.
(26 May 2017)
Vascular-targeted photodynamic therapy: a glimpse in the future of Urology?
Translational Cancer Research
2017;
6
(Suppl 3)
:S486-S488
.
(26 May 2017)
METLung: a disappointing result in a challenging patient population
Translational Cancer Research
2017;
6
(Suppl 3)
:S489-S493
.
(26 May 2017)
Osimertinib for EGFR T790M positive non-small cell lung cancer—making it happen, turning good idea into great results
Translational Cancer Research
2017;
6
(Suppl 3)
:S494-S497
.
(26 May 2017)
Characterizing advanced or metastatic adenocarcinoma of lung— one step closer?
Translational Cancer Research
2017;
6
(Suppl 3)
:S498-S501
.
(26 May 2017)
Targeting Bruton’s tyrosine kinase expression levels through microRNAs in chronic lymphocytic leukemia treatment
Translational Cancer Research
2017;
6
(Suppl 3)
:S502-S507
.
(26 May 2017)
Gefitinib in combination with pemetrexed in patients with advanced non-small cell lung cancer harboring EGFR mutations: is there any difference in acquired resistance mechanism between gefitinib monotherapy and the combination treatment?
Translational Cancer Research
2017;
6
(Suppl 3)
:S508-S511
.
(26 May 2017)
Bacteriogenic magnetic nanoparticles as magnetic resonance imaging contrast agents
Translational Cancer Research
2017;
6
(Suppl 3)
:S512-S514
.
(26 May 2017)
What can we learn from 3 phase III trials of ASCEND-4: ceritinib vs. platinum/pemetrexed with pemetrexed maintenance, PROFILE 1004: crizotinib vs. platinum/pemetrexed, and J-ALEX: alectinib vs. crizotinib?
Translational Cancer Research
2017;
6
(Suppl 3)
:S515-S518
.
(26 May 2017)
Cancer therapy by targeting the Warburg effect with miR-143 and response monitoring with 18F-FDG PET
Translational Cancer Research
2017;
6
(Suppl 3)
:S519-S521
.
(26 May 2017)
Targeting angiogenesis in small cell lung cancer
Translational Cancer Research
2017;
6
(Suppl 3)
:S522-S528
.
(26 May 2017)
The pathogenesis of follicular lymphoma, beyond apoptosis resistance
Translational Cancer Research
2017;
6
(Suppl 3)
:S529-S532
.
(26 May 2017)
Upfront radiation versus EGFR-TKI: which is the best approach for EGFR-mutated NSCLC patients with brain metastasis?
Translational Cancer Research
2017;
6
(Suppl 3)
:S533-S536
.
(26 May 2017)
Bevacizumab in extensive-disease small cell lung cancer: the search continues
Translational Cancer Research
2017;
6
(Suppl 3)
:S537-S538
.
(26 May 2017)
Angiogenesis inhibitors for small cell lung cancer
Translational Cancer Research
2017;
6
(Suppl 3)
:S539-S540
.
(26 May 2017)
The success of NRG-GBM-RPA: biomarker-based classification, where to next?
Translational Cancer Research
2017;
6
(Suppl 3)
:S541-S543
.
(26 May 2017)
Transarterial chemoembolization (TACE) combined with Sorafenib is more effective than TACE for hepatocellular carcinoma with portal vein tumor thrombus
Translational Cancer Research
2017;
6
(Suppl 3)
:S544-S546
.
(26 May 2017)
Is it time to consider the sentinel lymph node mapping the new standard in endometrial cancer?
Translational Cancer Research
2017;
6
(Suppl 3)
:S547-S552
.
(26 May 2017)
Harmonization of programmed cell death ligand-1 diagnostic assays in non-small cell lung cancer
Translational Cancer Research
2017;
6
(Suppl 3)
:S553-S556
.
(26 May 2017)
Promising results from Checkmate 012: better patients or better immunotherapy?
Translational Cancer Research
2017;
6
(Suppl 3)
:S557-S559
.
(26 May 2017)
Improving the safety of associating liver partition and portal vein ligation for staged hepatectomy
Translational Cancer Research
2017;
6
(Suppl 3)
:S560-S563
.
(26 May 2017)
Aneuploidy meets network analysis: leveraging copy number alterations to identify molecular pathways disrupted in high-grade serous ovarian carcinomas
Translational Cancer Research
2017;
6
(Suppl 3)
:S564-S568
.
(26 May 2017)
RIPK1 and allies in the battle against hepatocyte apoptosis and liver cancer
Translational Cancer Research
2017;
6
(Suppl 3)
:S569-S577
.
(26 May 2017)
Branched chain amino acid metabolism and cancer: the importance of keeping things in context
Translational Cancer Research
2017;
6
(Suppl 3)
:S578-S584
.
(26 May 2017)
Targeting cancer with tumor-specific therapeutic strategies—metabolic reprogramming beyond the Warburg effect
Translational Cancer Research
2017;
6
(Suppl 3)
:S585-S586
.
(26 May 2017)
Commentary on “The MLL1-H3K4me3 axis-mediated PD-L1 expression and pancreatic cancer immune evasion”
Translational Cancer Research
2017;
6
(Suppl 3)
:S587-S589
.
(26 May 2017)
Haploinsufficiency and mutation are two sides of the cancer coin as cause and therapeutics target
Translational Cancer Research
2017;
6
(Suppl 3)
:S590-S593
.
(26 May 2017)
Getting to know ovarian cancer spheroid: opportunity for spheroid-targeted therapy
Translational Cancer Research
2017;
6
(Suppl 3)
:S594-S597
.
(26 May 2017)
Direct-acting antiviral treatment for hepatitis C in liver transplant candidates and recipients
Translational Cancer Research
2017;
6
(Suppl 3)
:S598-S602
.
(26 May 2017)
STAT3: a crucial target for ovarian cancer stem cells that inhibits WNT signaling through a novel epigenetic mechanism
Translational Cancer Research
2017;
6
(Suppl 3)
:S603-S605
.
(26 May 2017)
Complement and disease: better no factor H than bad factor H
Translational Cancer Research
2017;
6
(Suppl 3)
:S606-S609
.
(26 May 2017)
Osimertinib a new weapon in epidermal growth factor receptor-mutated non-small cell lung cancer patients
Translational Cancer Research
2017;
6
(Suppl 3)
:S610-S613
.
(26 May 2017)
Potential role of antiestrogens in treating ovarian cancer
Translational Cancer Research
2017;
6
(Suppl 3)
:S614-S616
.
(26 May 2017)
Ramucirumab efficacy in first-line gastric and esophageal cancer treatment
Translational Cancer Research
2017;
6
(Suppl 3)
:S617-S621
.
(26 May 2017)
Fishing therapeutic T-cell receptors in healthy donor blood, is safety predictable?
Translational Cancer Research
2017;
6
(Suppl 3)
:S622-S624
.
(26 May 2017)
Neoadjuvant versus definitive chemoradiation for locally advanced esophageal squamous cell carcinoma
Translational Cancer Research
2017;
6
(Suppl 3)
:S625-S628
.
(26 May 2017)
Epigenetic mutations and cancer therapy Effectiven(EZH2)
Translational Cancer Research
2017;
6
(Suppl 3)
:S629-S634
.
(26 May 2017)
The role of in-bore magnetic resonance imaging guided biopsy for the detection of clinically significant prostate cancer
Translational Cancer Research
2017;
6
(Suppl 3)
:S635-S636
.
(26 May 2017)
Editorial on combination treatment beyond sorafenib alone for hepatocellular carcinoma with portal vein tumor thrombosis
Translational Cancer Research
2017;
6
(Suppl 3)
:S637-S642
.
(26 May 2017)
Ceritinib and cabozantinib: new tyrosine kinase inhibitors improve treatment options for non-small cell lung cancer patients
Translational Cancer Research
2017;
6
(Suppl 3)
:S643-S646
.
(26 May 2017)
How upfront can we be about upfront therapy for brain metastases in patients with activating epidermal growth factor receptor mutation?
Translational Cancer Research
2017;
6
(Suppl 3)
:S647-S649
.
(26 May 2017)
Letter to the Editor
Liver resection for hepatocellular carcinoma associated with portal vein tumor thrombus
Translational Cancer Research
2017;
6
(Suppl 3)
:S650-S651
.
(26 May 2017)
Epigenetic regulation of PD-L1 expression and pancreatic cancer response to checkpoint immunotherapy
Translational Cancer Research
2017;
6
(Suppl 3)
:S652-S654
.
(26 May 2017)
Disclosure:
This supplement was published without any sponsorship or funding.
